Dalutrafusp alfa clinical trials
Also written AGEN1423.
How each study uses dalutrafusp alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dalutrafusp alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Bruno Bockorny (1) · Weill Medical College of Cornell University (1) · Gilead Sciences (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test dalutrafusp alfa.
- Dec 2026Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver MetastasesPhase 2 · Weill Medical College of Cornell University
Studies
Open first, then newest update. How each study uses dalutrafusp alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver MetastasesRecruitingPhase 2Weill Medical College of Cornell UniversityNCT06300463Written as AGEN1423
- AGEN1423 and Botensilimab w/ or w/o Chemo in PDACActive, not recruitingPhase 2Bruno BockornyNCT05632328Written as AGEN1423
- Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid TumorsTerminatedPhase 1Gilead SciencesNCT03954704Written as Dalutrafusp alfa
Codes
What other systems call dalutrafusp alfa · ClinicalTrials.gg INT017081
- UNII (FDA) KNL22F1WCKDALUTRAFUSP ALFAOne source FDA
- NCI Thesaurus C167206Dalutrafusp AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KNL22F1WCK | DALUTRAFUSP ALFA | One source FDA |
| NCI Thesaurus | C167206 | Dalutrafusp Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.